EU/3/15/1486

On 24 April 2015, orphan designation (EU/3/15/1486) was granted by the European Commission to Clinipace GmbH, Germany, for recombinant human mesencephalic astrocyte-derived neurotrophic factor for the treatment of retinitis pigmentosa.

The sponsorship was transferred to Amarantus Europe Limited, United Kingdom in September 2016 and subsequently to RegIntel Limited, Ireland, in November 2016.

What is retinitis pigmentosa?

Retinitis pigmentosa is a group of hereditary diseases of the eye that lead to progressive loss of sight. In patients with retinitis pigmentosa, cells in the retina (the light-sensitive surface at the back of the eye) become damaged and eventually die.

Retinitis pigmentosa is a long-term debilitating disease because it causes the patient’s sight to get worse, eventually leading to blindness.

What is the estimated number of patients affected by the condition?

At the time of designation, retinitis pigmentosa affected approximately 3 in 10,000 people in the European Union (EU). This was equivalent to a total of around 154,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This isbased on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

---

*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 512,900,000 (Eurostat 2015).

What treatments are available?

At the time of designation, no satisfactory methods were authorised in the EU for treating retinitis pigmentosa. Patients with the condition were given sunglasses to slow down the damage to the retina, genetic counselling (discussion of the risks of passing the condition on to children) and general support.

How is this medicine expected to work?

It is thought that in patients with retinitis pigmentosa the death of retinal cells may be linked to problems with a structure inside the cells called the endoplasmic reticulum, which is involved in the production of proteins and helps them to fold properly. When retinal cells are stressed in patients with the condition, proteins may misfold and accumulate, resulting in the death of the cells.

The medicine consists of a human protein called ‘mesencephalic astrocyte-derived neurotrophic factor’ (MANF) which is thought to be normally produced in response to stress and to assist with the correct folding of proteins. By reducing the build-up of misfolded proteins under stress, MANF is expected to help retinal cells to survive.

The medicine is produced by a method known as ‘recombinant DNA technology’: it is made by cells into which a gene (DNA) has been introduced, which makes them able to produce MANF.

What is the stage of development of this medicine?

At the time of submission of the application for orphan designation, the evaluation of the effects of the medicine in experimental models was ongoing.

At the time of submission of the application for orphan designation, no clinical trials with the medicine in patients with retinitis pigmentosa had been started.

At the time of submission, the medicine was not authorised anywhere in the EU for retinitis pigmentosa. Orphan designation had been granted for this medicine in the United States for this condition.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 19 March 2015 recommending the granting of this designation.

Opinions on orphan medicinal product designations are based on the following three criteria:

• the seriousness of the condition;
• the existence of alternative methods of diagnosis, prevention or treatment;
• either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.